Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.

Kell SA, Kachura MA, Renn A, Traquina P, Coffman RL, Campbell JD.

Int Immunopharmacol. 2019 Jan;66:296-308. doi: 10.1016/j.intimp.2018.11.019. Epub 2018 Nov 29.

PMID:
30502651
2.

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.

Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS.

Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28.

3.

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen R, Candia AF, Coffman RL, Levy R.

Cancer Discov. 2018 Oct;8(10):1258-1269. doi: 10.1158/2159-8290.CD-18-0743. Epub 2018 Aug 28.

4.

Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-cell Interplay.

Gallotta M, Assi H, Degagné É, Kannan SK, Coffman RL, Guiducci C.

Cancer Res. 2018 Sep 1;78(17):4943-4956. doi: 10.1158/0008-5472.CAN-18-0729. Epub 2018 Jun 26.

5.

First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-Tolerated.

Jackson S, Candia AF, Delaney S, Floettmann S, Wong C, Campbell JD, Kell S, Lum J, Hessel EM, Traquina P, McHale M, Robinson I, Bell J, Fuhr R, Keeling D, Coffman RL.

Clin Pharmacol Ther. 2018 Aug;104(2):335-345. doi: 10.1002/cpt.938. Epub 2017 Dec 6.

PMID:
29134633
6.

Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.

Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, Varner JA, Pu M, Messer KS, Guiducci C, Coffman RL, Kitaura K, Matsutani T, Suzuki R, Carson DA, Hayashi T, Cohen EE.

JCI Insight. 2017 Sep 21;2(18). pii: 93397. doi: 10.1172/jci.insight.93397. eCollection 2017 Sep 21.

7.

Familial Creutzfeldt-Jakob Disease Cluster Among an African American Family.

Johnson MG, Bradley KK, Coffman RL, Belay ED.

J Public Health Manag Pract. 2017 Nov/Dec;23(6):614-617. doi: 10.1097/PHH.0000000000000464.

PMID:
27997483
8.

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.

Wang S, Campos J, Gallotta M, Gong M, Crain C, Naik E, Coffman RL, Guiducci C.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249. Epub 2016 Oct 31.

9.

Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen.

Milley B, Kiwan R, Ott GS, Calacsan C, Kachura M, Campbell JD, Kanzler H, Coffman RL.

Bioconjug Chem. 2016 May 18;27(5):1293-304. doi: 10.1021/acs.bioconjchem.6b00107. Epub 2016 May 8.

10.

Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9.

Garcia-Martinez I, Santoro N, Chen Y, Hoque R, Ouyang X, Caprio S, Shlomchik MJ, Coffman RL, Candia A, Mehal WZ.

J Clin Invest. 2016 Mar 1;126(3):859-64. doi: 10.1172/JCI83885. Epub 2016 Jan 25.

11.

A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.

Kachura MA, Hickle C, Kell SA, Sathe A, Calacsan C, Kiwan R, Hall B, Milley R, Ott G, Coffman RL, Kanzler H, Campbell JD.

J Immunol. 2016 Jan 1;196(1):284-97. doi: 10.4049/jimmunol.1501903. Epub 2015 Nov 25.

12.

OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response.

Jacquemin C, Schmitt N, Contin-Bordes C, Liu Y, Narayanan P, Seneschal J, Maurouard T, Dougall D, Davizon ES, Dumortier H, Douchet I, Raffray L, Richez C, Lazaro E, Duffau P, Truchetet ME, Khoryati L, Mercié P, Couzi L, Merville P, Schaeverbeke T, Viallard JF, Pellegrin JL, Moreau JF, Muller S, Zurawski S, Coffman RL, Pascual V, Ueno H, Blanco P.

Immunity. 2015 Jun 16;42(6):1159-70. doi: 10.1016/j.immuni.2015.05.012. Epub 2015 Jun 9.

13.

A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.

Ray A, Tian Z, Das DS, Coffman RL, Richardson P, Chauhan D, Anderson KC.

Leukemia. 2014 Aug;28(8):1716-24. doi: 10.1038/leu.2014.46. Epub 2014 Jan 30.

14.

A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice.

Campbell JD, Kell SA, Kozy HM, Lum JA, Sweetwood R, Chu M, Cunningham CR, Salamon H, Lloyd CM, Coffman RL, Hessel EM.

Thorax. 2014 Jun;69(6):565-573. doi: 10.1136/thoraxjnl-2013-204605. Epub 2014 Jan 24.

15.

RNA recognition by human TLR8 can lead to autoimmune inflammation.

Guiducci C, Gong M, Cepika AM, Xu Z, Tripodo C, Bennett L, Crain C, Quartier P, Cush JJ, Pascual V, Coffman RL, Barrat FJ.

J Exp Med. 2013 Dec 16;210(13):2903-19. doi: 10.1084/jem.20131044. Epub 2013 Nov 25.

16.

Converging discoveries: the first reports of IL-4.

Coffman RL.

J Immunol. 2013 Feb 1;190(3):847-8. doi: 10.4049/jimmunol.1203368. No abstract available.

17.

Current strategies for allergen-specific immunotherapy at its centenary.

Valenta R, Coffman RL.

Curr Top Microbiol Immunol. 2011;352:v-vi. No abstract available.

PMID:
22145167
18.

Assessing the safety of adjuvanted vaccines.

Ahmed SS, Plotkin SA, Black S, Coffman RL.

Sci Transl Med. 2011 Jul 27;3(93):93rv2. doi: 10.1126/scitranslmed.3002302. Review.

PMID:
21795590
19.

Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus.

Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V.

Sci Transl Med. 2011 Mar 9;3(73):73ra20. doi: 10.1126/scitranslmed.3001201.

20.

Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response.

Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, DeFranco AL.

Immunity. 2011 Mar 25;34(3):375-84. doi: 10.1016/j.immuni.2011.01.011. Epub 2011 Feb 25.

21.

Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9.

Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo MP, Coffman RL, Barrat FJ.

J Exp Med. 2010 Dec 20;207(13):2931-42. doi: 10.1084/jem.20101048. Epub 2010 Nov 29.

22.

Vaccine adjuvants: putting innate immunity to work.

Coffman RL, Sher A, Seder RA.

Immunity. 2010 Oct 29;33(4):492-503. doi: 10.1016/j.immuni.2010.10.002. Review.

23.

Hemolytic Uremic Syndrome After an Escherichia coli O111 Outbreak.

Piercefield EW, Bradley KK, Coffman RL, Mallonee SM.

Arch Intern Med. 2010 Oct 11;170(18):1656-63. doi: 10.1001/archinternmed.2010.346.

PMID:
20937925
24.

TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus.

Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, Chan JH, Wright T, Punaro M, Bolland S, Soumelis V, Banchereau J, Coffman RL, Pascual V, Barrat FJ.

Nature. 2010 Jun 17;465(7300):937-41. doi: 10.1038/nature09102.

25.

Immunology. The origin of TH2 responses.

Coffman RL.

Science. 2010 May 28;328(5982):1116-7. doi: 10.1126/science.1192009. No abstract available.

PMID:
20508120
26.

Allergen-specific T cell responses to immunotherapy monitored by CD154 and intracellular cytokine expression.

Campbell JD, Buchmann P, Kesting S, Cunningham CR, Coffman RL, Hessel EM.

Clin Exp Allergy. 2010 Jul;40(7):1025-35. doi: 10.1111/j.1365-2222.2010.03505.x. Epub 2010 Apr 13.

PMID:
20412135
27.

CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans.

Campbell JD, Cho Y, Foster ML, Kanzler H, Kachura MA, Lum JA, Ratcliffe MJ, Sathe A, Leishman AJ, Bahl A, McHale M, Coffman RL, Hessel EM.

J Clin Invest. 2009 Sep;119(9):2564-76. doi: 10.1172/JCI38294. Epub 2009 Aug 10.

28.

Biomarkers measuring the activity of Toll-like receptor ligands in clinical development programs.

Sims P, Coffman RL, Hessel EM.

Methods Mol Biol. 2009;517:415-40. doi: 10.1007/978-1-59745-541-1_25.

PMID:
19378019
29.
30.
31.

Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections.

Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Barrat FJ, Coffman RL, Staprans SI, Feinberg MB.

Nat Med. 2008 Oct;14(10):1077-87. doi: 10.1038/nm.1871. Epub 2008 Sep 14.

PMID:
18806803
32.

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.

Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM.

Clin Cancer Res. 2008 Sep 1;14(17):5626-34. doi: 10.1158/1078-0432.CCR-08-0526.

33.

Development of TLR inhibitors for the treatment of autoimmune diseases.

Barrat FJ, Coffman RL.

Immunol Rev. 2008 Jun;223:271-83. doi: 10.1111/j.1600-065X.2008.00630.x. Review.

PMID:
18613842
34.

PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation.

Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, Barrat FJ, Soumelis V.

J Exp Med. 2008 Feb 18;205(2):315-22. doi: 10.1084/jem.20070763. Epub 2008 Jan 28.

35.
36.

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.

Kanzler H, Barrat FJ, Hessel EM, Coffman RL.

Nat Med. 2007 May;13(5):552-9. Review.

PMID:
17479101
37.

Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response.

Yarovinsky F, Kanzler H, Hieny S, Coffman RL, Sher A.

Immunity. 2006 Oct;25(4):655-64. Epub 2006 Sep 28.

38.

Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation.

Guiducci C, Ott G, Chan JH, Damon E, Calacsan C, Matray T, Lee KD, Coffman RL, Barrat FJ.

J Exp Med. 2006 Aug 7;203(8):1999-2008. Epub 2006 Jul 24.

39.

Origins of the T(H)1-T(H)2 model: a personal perspective.

Coffman RL.

Nat Immunol. 2006 Jun;7(6):539-41.

PMID:
16715060
40.

Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses.

Gauvreau GM, Hessel EM, Boulet LP, Coffman RL, O'Byrne PM.

Am J Respir Crit Care Med. 2006 Jul 1;174(1):15-20. Epub 2006 Mar 30.

PMID:
16574937
41.

Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction.

Hessel EM, Chu M, Lizcano JO, Chang B, Herman N, Kell SA, Wills-Karp M, Coffman RL.

J Exp Med. 2005 Dec 5;202(11):1563-73. Epub 2005 Nov 28.

42.

Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses.

Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, Picard C, von Bernuth H, Senechal B, Plancoulaine S, Al-Hajjar S, Al-Ghonaium A, Maródi L, Davidson D, Speert D, Roifman C, Garty BZ, Ozinsky A, Barrat FJ, Coffman RL, Miller RL, Li X, Lebon P, Rodriguez-Gallego C, Chapel H, Geissmann F, Jouanguy E, Casanova JL.

Immunity. 2005 Nov;23(5):465-78.

43.

Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus.

Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL.

J Exp Med. 2005 Oct 17;202(8):1131-9.

44.

Surface phenotype of Peyer's patch germinal center cells: implications for the role of germinal centers in B cell differentiation. 1982.

Butcher EC, Rouse RV, Coffman RL, Nottenburg CN, Hardy RR, Weissman IL.

J Immunol. 2005 Aug 1;175(3):1363-72. No abstract available.

45.

Airway generation-specific differences in the spatial distribution of immune cells and cytokines in allergen-challenged rhesus monkeys.

Miller LA, Hurst SD, Coffman RL, Tyler NK, Stovall MY, Chou DL, Putney LF, Gershwin LJ, Schelegle ES, Plopper CG, Hyde DM.

Clin Exp Allergy. 2005 Jul;35(7):894-906.

46.

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986.

Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL.

J Immunol. 2005 Jul 1;175(1):5-14. No abstract available.

47.

Nonhuman primate models of asthma.

Coffman RL, Hessel EM.

J Exp Med. 2005 Jun 20;201(12):1875-9.

48.

Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation.

Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL, Barrat FJ.

J Immunol. 2005 May 1;174(9):5193-200.

49.

T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells.

Fahlén L, Read S, Gorelik L, Hurst SD, Coffman RL, Flavell RA, Powrie F.

J Exp Med. 2005 Mar 7;201(5):737-46.

50.

Superior activity of the type C class of ISS in vitro and in vivo across multiple species.

Marshall JD, Fearon KL, Higgins D, Hessel EM, Kanzler H, Abbate C, Yee P, Gregorio J, Cruz TD, Lizcano JO, Zolotorev A, McClure HM, Brasky KM, Murthy KK, Coffman RL, Nest GV.

DNA Cell Biol. 2005 Feb;24(2):63-72.

PMID:
15699627

Supplemental Content

Loading ...
Support Center